YK11, ACE-031, and myostatin inhibition: hype vs. human data

What did @jonnascoach actually say?

Honestly? It's hard to tell. The transcript here is largely incoherent, referencing "Victoria Valley," tobacco, money, and bodybuilding in a sequence that doesn't hang together as a coherent argument. The hashtags, however, tell a clearer story: this video is framed around myostatin inhibition, YK11, and ACE-031, three compounds that have become fixtures of extreme muscle-growth content on TikTok. The actual spoken content is either badly transcribed, auto-translated from Spanish, or both. What we can assess is what these hashtags represent and whether the implied claims about these compounds hold up to scrutiny.

Given the caption and hashtag context, the video appears to be promoting the idea that myostatin inhibition, whether through YK11 or ACE-031, is a viable and perhaps accessible tool for bodybuilders. That's the claim worth examining.

Does the science back this up?

Partially, and with enormous caveats. Myostatin is a real protein that limits muscle growth. Blocking it does increase muscle mass in animal models. But the leap from "this works in mice" to "take this compound" is where influencer content consistently falls apart.

YK11 is often labeled a SARM, but it's more accurately described as a synthetic steroidal compound that may partially inhibit myostatin while also binding androgen receptors. The research base is thin. A 2018 cell study by Yatsu et al. in Biological and Pharmaceutical Bulletin confirmed androgen receptor partial agonism in vitro, but there are zero completed human clinical trials on YK11 for muscle growth. ACE-031, a myostatin inhibitor developed by Acceleron Pharma, was tested in humans in clinical trials for Duchenne muscular dystrophy. A 2013 trial by Attie et al. in Muscle and Nerve showed muscle mass increases but was halted due to adverse effects including nosebleeds, gum bleeding, and telangiectasia. That's a drug that failed its own clinical development. Presenting either compound as a straightforward bodybuilding tool ignores this record entirely.

What did they get wrong (or right)?

Without a clear spoken claim, we're grading the framing. The framing is misleading. Presenting YK11 and ACE-031 together as sports pharmacology tools, without discussing that ACE-031 never reached approval and was abandoned due to safety signals, is a significant omission. YK11 has no human safety data worth citing in its favor. Hepatotoxicity concerns with steroidal compounds in this class are real, and there are published case reports of liver injury in users of unregulated SARMs broadly.

What the video arguably gets right, implicitly, is that myostatin is a legitimate biological target. The science on myostatin's role in muscle regulation is solid. Lee and McPherron's foundational 1997 work in Nature established this clearly. The problem is the distance between "myostatin matters" and "here's how to block it safely" is enormous, and that distance is where most of the risk lives.

What should you actually know?

If you're interested in myostatin biology because you want to optimize muscle development, here's the honest version. No approved myostatin inhibitor exists for healthy adults. Compounds sold online as YK11 are unregulated, of unknown purity, and have no established human dosing safety data. ACE-031 is not commercially available and was shelved. Follistatin-based peptides get discussed in the same breath, but the clinical evidence for those in healthy populations is similarly thin.

The broader category of myostatin-targeting compounds represents one of the more genuinely interesting areas of muscle biology research, particularly for conditions like cachexia and muscular dystrophy. But interesting research does not equal safe supplementation. A compound that causes bleeding complications in a controlled trial is not a candidate for unsupervised use. Anyone presenting these compounds as routine sports pharmacology is either uninformed or unconcerned about the gap between animal data and human safety.